Overview
Stephen Chambers serves as Managing Director & General Partner at SOSV NY at SOSV[1][3]. Chambers holds a BS in Biochemistry from Bangor University, an MS in Biotechnology from the University of Birmingham, and a PhD in Molecular Biology from the University of Warwick[10][11][12]. Chambers worked at Vertex Pharmaceuticals as Director of Gene Expression from 1990 to 2013[9], then co-founded Abpro from 2008 to 2013[8]. Chambers subsequently served as CEO of SynbiCITE and Advisory Board Member of London DNA Foundry from 2014 to 2018[6][7], co-founded Bio-start from 2016 to 2018[5], and held the position of Royal Society Entrepreneur in Residence at Imperial College London from 2019 to 2021[4].
Profile introduction
I left the UK because the US was where scientists were building companies. So that's where I went. I joined Vertex Pharmaceuticals (NASDAQ:VRTX) as a founding scientist, where I got to see firsthand how great science becomes FDA-approved medicine. From there I co-founded Abpro Therapeutics (NASDAQ:ABP), using synthetic biology to rethink how antibodies are discovered and developed. Along the way I figured out that I loved building companies just as much as I loved the science, maybe more. There's a pattern to where I've chosen to be. When I arrived in the US, Boston/Cambridge were just start…
Career history
- Managing Director & General Partner at SOSV NYMar 2020 to presentSOSV
- Royal Society Entrepreneur in Residence2019 to 2021Imperial College London
- Co FounderAug 2016 to Jul 2018Bio-start
- CEO2014 to 2018SynbiCITE
- Advisory Board Member2014 to 2018London DNA Foundry
- Co Founder2008 to 2013Abpro
- Director of Gene Expression1990 to 2007Vertex Pharmaceuticals
Education
PhD, Molecular BiologyUniversity of Warwick
- MS, BiotechnologyUniversity of Birmingham
- BS, BiochemistryBangor University
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.